The use of moxonidine in the treatment of arterial hypertension

Česká verzia

Authors: Jan Vachek
Authors place of work: Interní oddělení Klatovské nemocnice a. s. ; Klinika nefrologie 1. LF UK a VFN v Praze
Published in the journal: Vnitř Lék 2021; 67(3): 170-172
Category: Review Articles

Summary

Moxonidine is an oral antihypertensive drug from the group of 2nd generation sympatholytics. In patients with mild to moderate hypertension, moxonidine lowers blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy – if appropriate, and is also an effective adjunctive therapy in combination with other antihypertensives. It improves metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is very well tolerated, has a low potential for drug interactions and is administered in a single daily dose. Thus, moxonidine is a good choice especially in the treatment of patients with more severe forms of hypertension, especially as adjunctive therapy in patients with metabolic syndrome or with mental stress.

Keywords:

arterial hypertension – Sympathetic nervous system – sympatholytics – moxonidine – metabolic syndrome

Zdroje

1. Widimský J, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Vnitř Lék 2018; 64: 771–796.

2. Hradec J. Klinické charakteristiky a farmakoterapie nemocných s chronickou ischemickou chorobou srdeční v České republice v roce 2018 – výsledky průřezového průzkumu. Medicína po promoci 2019; 20: 225–231.

3. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries.Circulation. 2016; 134: 441–450.

4. Mulé G, Cottone S, Nardi E, Andronico G, Cerasola G. Minerva Cardioangiol. 2006; 54(2): 173–194.

5. Mulè G, Cerasola G. J Clin Hypertens (Greenwich). 2006; 8(3): 195–201.

6. Balasubramanian P, Hall D, Subramanian M. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases. Geroscience. 2019; 41(1): 13–24. doi:10.1007/s11357-018-0048-5

7. AlGhatrif M, Strait JB, Morrell CH, Canepa M, Wright J, Elango P, Scuteri A, Najjar SS, Ferrucci L, Lakatta EG. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. Hypertension. 2013; 62(5): 934–941.

8. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev. 1994; 74(2): 323–364.

9. Lüllmann, Mohr, Wehling: Pharmakologie und Toxikologie. (15. Auflage, 2006)

10. Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: A review of its use in essential hypertension. Drugs 2006; 66: 477–496.

11. Küppers H, Jäger BA, Luscik J, Gräve M, Hughes P, Kaan EC. Placeboand enalapril-controlled evaluation of the efficacy and tolerability of once-daily moxonidine in mild to moderate hypertension. Zitiert bei Prichard BNC, Graham BR. J Cardiovasc Pharmacol 1996; 27(Suppl 3): 38. 10.

12. Krentz AJ, Evans AJ. Selective imidazoline receptor agonists for metabolic syndrome. Lancet 1998; 351: 152

13. The MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659–667.

14. Platná SPC jednotlivých přípravků s moxonidinem (www.sukl.cz)

15. Karow T, Lang-Roth R. Allgemeine und Spezielle Pharmakologie und Toxikologie 2021. Thomas Karow (Verlag), 2020 | 29. Auflage.